The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome

for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Network

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: (1) To evaluate the direct (un-mediated) and indirect (mediated) relationship between antenatal exposure to opioid agonist medication as treatment for opioid use disorder (MOUD) and the severity of neonatal opioid withdrawal syndrome (NOWS), and (2) to understand the degree to which mediating factors influence the direct relationship between MOUD exposure and NOWS severity. Methods: This cross-sectional study includes data abstracted from the medical records of 1294 opioid-exposed infants (859 MOUD exposed and 435 non-MOUD exposed) born at or admitted to one of 30 US hospitals from July 1, 2016, to June 30, 2017. Regression models and mediation analyses were used to evaluate the relationship between MOUD exposure and NOWS severity (i.e., infant pharmacologic treatment and length of newborn hospital stay (LOS)) to identify potential mediators of this relationship in analyses adjusted for confounding factors. Results: A direct (un-mediated) association was found between antenatal exposure to MOUD and both pharmacologic treatment for NOWS (aOR 2.34; 95%CI 1.74, 3.14) and an increase in LOS (1.73 days; 95%CI 0.49, 2.98). Delivery of adequate prenatal care and a reduction in polysubstance exposure were mediators of the relationship between MOUD and NOWS severity and as thus, were indirectly associated with a decrease in both pharmacologic treatment for NOWS and LOS. Conclusions for Practice: MOUD exposure is directly associated with NOWS severity. Prenatal care and polysubstance exposure are potential mediators in this relationship. These mediating factors may be targeted to reduce the severity of NOWS while maintaining the important benefits of MOUD during pregnancy.

Original languageEnglish
Pages (from-to)1030-1042
Number of pages13
JournalMaternal and Child Health Journal
Volume27
Issue number6
DOIs
StatePublished - Jun 2023

Keywords

  • Length of stay (LOS)
  • Medication for opioid withdrawal syndrome (MOUD)
  • Neonatal opioid withdrawal syndrome (NOWS)
  • Pharmacologic treatment
  • Polysubstance exposure
  • Prenatal care
  • Parturition
  • Cross-Sectional Studies
  • Humans
  • Analgesics, Opioid/adverse effects
  • Infant
  • Opioid-Related Disorders/complications
  • Neonatal Abstinence Syndrome/drug therapy
  • Pregnancy
  • Female
  • Infant, Newborn

Fingerprint

Dive into the research topics of 'The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome'. Together they form a unique fingerprint.

Cite this